San Diego, Calif – June 9, 2020 — Crown Bioscience today announced the presentation of new, proprietary NAFLD/NASH preclinical model development data. The data will be available at the American Diabetes Association (ADA) 80th Scientific Sessions, as well as CrownBio’s own complementary virtual event.
The new data shares development of NAFLD/NASH models generated through dietary modifications across CrownBio’s repertoire of highly translational rodent and NHP preclinical models. The models will enable enhanced preclinical NAFLD/NASH drug development, a disease area currently lacking approved therapies.
Alongside ADA 2020 posters, CrownBio is also supporting the concurrent International NASH Day on June 12th with a NAFLD/NASH model development presentation. CrownBio is hosting a free virtual event, providing access to all of these resources, which is registered for at CrownBio.com/ADA20.
“We’re committed to furthering and accelerating NAFLD/NASH research, by continuing to enhance our platform of highly translational preclinical models” said Dr. Jim Wang, senior vice president of cardiovascular and metabolic disease at CrownBio. “We’re delighted to be able to share our latest research in this area of high unmet need across a range of innovative virtual events this June”.
CrownBio’s virtual ADA event occurs from June 12th to 16th at CrownBio.com/ADA20, and will allow discussion with the CrownBio cardiovascular and metabolic disease team, as well as the review and download of a wide range of resources across disease areas including NAFLD/NASH, diabetes, obesity, renal and cardiovascular diseases.
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit www.crownbio.com.
Contact details
-
- Louise Stenson
-
Crown Bioscience Company Inquiries
Communications Manager - louise.stenson@crownbio.com
Related topics
Related news
Crown Bioscience Partners with CTI to Support Consulting Services in Oncology Drug Development
Crown Bioscience announces a strategic partnership with Clinical Trial & Consulting Services (CTI), a renowned global full-spectrum research service provider, to bolster oncology-focused consulting...
Crown Bioscience Enters Global Agreement with Shanghai Model Organisms Center
Crown Bioscience announces the completion of a global collaboration agreement with the Shanghai Model Organism Center (SMOC). This five-year agreement extends the existing partnership and will prov...
Crown Bioscience Achieves CAP 15189 Accreditation; ISO 15189 Standard for Quality Medical Laboratory Services
Crown Bioscience today announced the dual attainment of College of American Pathologists (CAP) accreditations for its medical laboratory services.
Crown Bioscience Introduces OrganoidXplore: Revolutionizing Cancer Research with Rapid Large-scale Organoid Drug Scre...
Crown Bioscience has launched OrganoidXplore, a revolutionary platform for large-scale screening of patient-derived organoids that accelerates preclinical oncology drug discovery. The platform repl...
Indivumed Services’ Hamburg Site Receives College of American Pathologists (CAP) Accreditation
Indivumed Services GmbH, a Crown Bioscience company, has received laboratory accreditation from the College of American Pathologists (CAP), highlighting its commitment to excellence in laboratory s...